Pricing and Reimbursement

A recent issue of Value in Health contains the ISPOR Special Task Force Report on US Value Assessment Frameworks. In this blog post, we summarise the Task Force Report and pick up key points made in the various response articles. We also highlight further OHE work in this area.

This report analyses patient access in the UK to new medicines authorised via the centralised procedure between 2011 and 2016.

Drug prices in the US might overstate pharmaceuticals' long-run cost up to 75%. True long-term costs then must be considered by market access and policy decisions.

The presentations delivered by OHE at the iHEA congress, July 2017, are available in this post.

The presentations delivered by OHE at the HTAi Annual Meeting, June 2017, are available in this post.

A new paper, Assessing Value, Budget Impact, and Affordability in Asia, has been published in the International Journal of Technology Assessment in Health Care. This paper summarises the authors’ views on key thoughts and suggestions emerging from the 2016 HTAi Asia Policy Forum (HAPF) meeting.

The 2017 iHEA congress will be held in Boston, 7th-11th July 2017. Members of the OHE team will be attending and participating in the conference, and would welcome the opportunity to meet with you.

A selection of the posters and presentations delivered by OHE at the ISPOR 22nd Annual...

The HTAi Annual Meeting 2017 will be held in Rome, Italy, 17-21st June 2017. The theme of the meeting is Towards an HTA Ecosystem: From Local Needs to Global Opportunities. Several members of the OHE team will attend and participate in the conference.

The fourth annual meeting of the HTAi Asia Policy Forum was held in November 2016. OHE produced Background Briefing Papers for each of these four meetings covering a variety of topics relevant to the development of HTA in Asia, all of which are now available. This post contains a summary of each report.

Pages

Subscribe to RSS - Pricing and Reimbursement